NEW YORK — MRC Holland said on Thursday that its blood-based assay for Temple, Kagami-Ogata, and Russell-Silver syndromes has received certification under Europe's In Vitro Diagnostic Regulation (IVDR ...
The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.
The company said that growth in its diagnostics business was partly offset by declines in the Americas and China.
Total revenues were $3.33 billion, up from $3.03 billion in the same quarter last year and slightly above the consensus Wall Street estimate of $3.31 billion.
The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.